Upgrade to SI Premium - Free Trial

Amgen (AMGN) Announces Meeting with U.S. FDA to Discuss ABP 501 BLA

July 12, 2016 7:32 AM
Amgen (Nasdaq: AMGN) announced that the Company will discuss data supporting the ABP 501 Biologics License Application (BLA) with the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Management Comments

Next Articles